a Novel Once Daily PI3K-Delta Inhibitor, Demonstrates Clinical Activity with a Favorable& Differentiated Safety Profile as a Single Agent and in Combination with a Novel Glyocengineered anti-CD20 mAb, Ublituximab in Patients with Rel/Ref CLL.

Download

Drug Category : Array

Conference Category : Array

Lead Author : O'Brien, et al.

Published Date : 09/09/2015

Download Link : https://www.tgtherapeutics.com/wp-content/uploads/2019/03/1202%201303%20iwCLL%202015%20FINAL.pdf

Download Text : Download

Popup Confirmation? :

site-sidebar-layout : default

ast-site-content-layout : default

site-content-style : default

site-sidebar-style : default

theme-transparent-header-meta : default

astra-migrate-meta-layouts : set

stick-header-meta : default